Verici Dx completes WRAP Retail Offer and raises additional gross proceeds

VRCI

Verici Dx Plc (LON:VRCI) has confirmed the result of its WRAP Retail Offer at the issue price of 0.35 pence per share, following the announcements made on 8 June 2026. The Company has raised aggregate gross proceeds of approximately £0.19 million pursuant to the WRAP Retail Offer in addition to the previously announced Placing. Accordingly, the Company will issue a total of 53,345,832 WRAP Retail Offer Shares.

In total, the Placing and the WRAP Retail Offer has raised gross proceeds of approximately £2.6 million for the Company, via the Placing of 700,000,000 Placing Shares and the 53,345,832 WRAP Retail Offer Shares.

For the avoidance of doubt, the WRAP Retail Offer is not part of the Placing. The issue of the WRAP Retail Offer Shares is conditional upon:

  • the passing of certain resolutions to be put to shareholders of Verici Dx plc at a General Meeting, which is expected to be held at Shoosmiths LLP’s London office at 1 Bow Churchyard, London EC4M 9DQ at 11.30 a.m. on 22 June 2026; and
  • the new Ordinary Shares being admitted to trading on AIM.

Terms used but not defined in this announcement have the same meaning as set out in the Company’s announcement released at 7am on 8 June 2026.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Verici Dx raises £8.75m through share placing as 2.69bn new shares join AIM

Verici Dx has completed its £8.75m fundraising, with 2.69 billion new ordinary shares admitted to trading on AIM. CEO...

Verici Dx expands kidney transplant research through US clinical trial agreement

Verici Dx has secured an order to provide PTRA and other blood-based biomarker testing for an Asahi Kasei Therapeutics...

Verici Dx secures Asahi Kasei Therapeutics order for phase 2 transplant trial

Verici Dx will provide blood-based biomarker testing, including its Pre-Transplant Risk Assessment assay, for a Phase 2 clinical trial...

Verici Dx raises £8.75m through Placing and Retail Offer

Verici Dx has raised £8.75 million through a placing and retail offer, with AIM trading set to resume on...

Verici Dx raises £8.5m and launches £250,000 retail share offer

Verici Dx has conditionally raised £8.5 million through a placing at 0.20 pence per share, with strong support from...

Verici Dx raises £8m to expand Tutivia commercialisation and fund growth

Verici Dx plans to raise approximately £8 million through a placing and retail offer, with funds supporting commercial team...

Search